J 2024

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium

BEYER, Katharina, Renee LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Frederique DENIJS et. al.

Basic information

Original name

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium

Authors

BEYER, Katharina, Renee LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Frederique DENIJS, Wichor BRAMER, Vera VASILYEVA, Erik BRIERS, Juan Gomez RIVAS, Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, van Poppel HENDRIK and Monique J ROOBOL

Edition

Journal of Personalized Medicine, Basel, MDPI, 2024, 2075-4426

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30304 Public and environmental health

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.508 in 2021

Organization unit

Faculty of Medicine

UT WoS

001151281700001

Keywords in English

prostate cancer; screening; early detection; policy; health policy

Tags

Tags

International impact, Reviewed
Změněno: 5/6/2024 09:58, Mgr. Tereza Miškechová

Abstract

V originále

With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.